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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to Vitis 
vinifera L. seeds extract and “helps to decrease swollen legs” pursuant to 
Article 13(5) of Regulation (EC) No 1924/20061 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vitis 
vinifera L. seeds extract and “helps to decrease swollen legs”. The Panel considers that the food constituent 
which is the subject of the health claim is sufficiently characterised. Upon EFSA’s request for clarification, the 
applicant stated that the claimed effect was “helps to decrease swollen legs”, and that the beneficial 
physiological effect could be related to “helps to refine legs”. In the context of the references provided for the 
scientific substantiation of the claim, and in particular of the human intervention study which was conducted 
with the food constituent that is the subject of the health claim, the Panel notes that the claim refers to the 
reduction of peripheral oedema in the context of chronic clinical conditions (e.g. chronic venous insufficiency) 
where the reduction of peripheral oedema is a therapeutic target for the treatment of the condition. The Panel 
considers that the reduction of peripheral oedema in the context of chronic clinical conditions is a therapeutic 
target for the treatment of the condition and does not comply with the criteria laid down in Regulation (EC) No 
1924/2006. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to Vitis vinifera L. seeds extract and “helps to decrease swollen legs”. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food constituent that is the subject of the health claim is an extract of Vitis vinifera L. seeds which 
is standardised by its content of polyphenols. The Panel considers that Vitis vinifera L. seeds extract is 
sufficiently characterised. 
The claimed effect proposed by the applicant is “helps to decrease swollen legs”. The target 
population proposed by the applicant is healthy adults in the general population. During the validation 
and evaluation processes, EFSA requested the applicant to identify the specific physiological function 
of the body that is the subject of the claim, together with the outcome measures which may be used for 
the scientific evaluation of that function. The applicant stated that the claimed effect was “helps to 
decrease swollen legs”, and that the beneficial physiological effect could be related to “helps to refine 
legs”.    
In the context of the references provided for the scientific substantiation of the claim, and in particular 
the human intervention study which was conducted with the food constituent that is the subject of the 
health claim, the Panel notes that the claim refers to the reduction of peripheral oedema in the context 
of chronic clinical conditions (e.g. chronic venous insufficiency) where the reduction of peripheral 
oedema is a therapeutic target for the treatment of the condition. 
The Panel considers that the reduction of peripheral oedema in the context of chronic clinical 
conditions is a therapeutic target for the treatment of the condition and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006. 
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BACKGROUND 
Regulation (EC) No 1924/20064 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
• The application was received on 06/03/2012. 
• The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
• On 30/03/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
• On 21/05/2012, EFSA received the missing information as submitted by the applicant.  
• The scientific evaluation procedure started on 31/05/2012. 
• On 12/09/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application. The clock was stopped on 21/09/2012 
and restarted on 06/10/2012, in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
• On 17/10/2012, EFSA received the requested information (which was made available to 
EFSA in electronic format on 05/10/2012). 
• During its meeting on 28/11/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Vitis vinifera L. 
seeds extract and “helps to decrease swollen legs”. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to: Vitis vinifera L. seeds extract and “helps to 
decrease swollen legs”. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of Vitis vinifera L. seeds extract, a positive assessment of its safety, nor a decision on whether Vitis 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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vinifera L. seeds extract is, or is not, classified as a foodstuff. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl, Chemin de Beau-rivage 7, Post code 96 CH-1000 
Lausanne 21, Switzerland. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent that is the subject of the health claim is grape seed 
extract. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is “helps to decrease swollen legs”. The applicant claims 
that swelling in lower limbs of women is accompanied by different signs such as heaviness of legs, 
swollen legs or painful legs sensations which are having a high impact on quality of life. In addition, 
the applicant claims that swollen leg is associated with an increase of fluid leakage due to an 
impairment of venous vein walls, and thus a decrease of swollen legs due to an improvement of 
venous vein walls function and an increase of capillary resistance is a beneficial physiological effect.  
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “helps to decrease swollen 
legs”. 
Alternative wordings: “helps to refine and lighten the legs”, “helps to reduce swollen legs sensation”, 
“helps to decrease excess water responsible for swollen legs sensation”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, 120 to 150 mg per day of grape seed extract should be consumed during a 
meal. The applicant has proposed healthy adults in the general population as the target population. 
ASSESSMENT 
1. Characterisation of the food/constituent  
The food constituent that is the subject of the health claim is an extract of Vitis vinifera L. seeds. 
Vitis vinifera L. (grape vine) is a perennial plant, originating from North and South Africa or South 
West Europe, which belongs to the Vitaceae family. The dry powder extract is obtained by extraction 
of seeds of Vitis vinifera L. with ethanol and ethyl acetate, and subsequent evaporation, filtration, 
concentration and spray-drying. The extract of Vitis vinifera L. seeds is standardised by its content of 
specific polyphenols: at least 35 % of gallic acid, catechins, epicatechins and procyanidin dimers B1, 
B2, B3 and B4. Procyanidin dimers account for at least 7% of the extract. These constituents can be 
analysed in foods by established methods. 
Upon EFSA’s request for additional information, the applicant clarified that the range given for the 
plant/extract ratio depended on the amount of polyphenols in the plant used to obtain the extract. 
Information pertaining to the manufacturing process, control specifications and batch-to-batch 
variability has been provided by the applicant. 
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The dry powder extract of Vitis vinifera L. seeds is proposed to be used in food supplements, with no 
reference to any specific formulation, in a quantity of 120-150 mg of extract per serving. 
The Panel considers that the food constituent, Vitis vinifera L. seeds extract, which is the subject of the 
health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “helps to decrease swollen legs”. The target 
population proposed by the applicant is healthy adults in the general population. 
During the validation process, EFSA requested the applicant to identify the specific physiological 
function of the body that is the subject of the claim, together with the outcome measures which may be 
used for the scientific evaluation of that function. The applicant stated that swollen legs were 
associated with an increase of fluid leakage due to an impairment of vein walls, that a decrease of 
swollen legs due to an improvement of venous wall function and an increase of capillary resistance 
was a beneficial physiological effect, and that the changes in swollen legs could be assessed by 
measuring the thickness of oedema by ultrasound.  
During the evaluation process, the Panel communicated to the applicant that “venous vein walls 
function” or “capillary resistance” had not been defined in the application, that “swollen legs 
measured as the thickness of oedema” was not a physiological function of the body but rather a non-
specific clinical symptom related to diseases of various aetiology, and that thickness of oedema was 
neither a direct measure of “venous wall function” nor of “capillary resistance”. The Panel also 
requested the applicant to clarify and identify the specific physiological function that is the subject of 
the health claim, together with the outcome measure(s) which may be used for the scientific evaluation 
of that function. The applicant replied that the claimed effect was “helps to decrease swollen legs” and 
that the beneficial physiological effect could be related to “helps to refine legs”. 
In the context of the references provided for the scientific substantiation of the claim (Allaert, 2009, 
unpublished; Djian et al., 2006), and in particular the human intervention study which was conducted 
with the food constituent that is the subject of the health claim (Allaert, 2009, unpublished), the Panel 
notes that the claim refers to the reduction of peripheral oedema in the context of chronic clinical 
conditions (e.g. chronic venous insufficiency) where the reduction of peripheral oedema is a 
therapeutic target for the treatment of the condition (EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA), 2012).  
The Panel considers that the reduction of peripheral oedema in the context of chronic clinical 
conditions is a therapeutic target for the treatment of the condition and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
• The food constituent, Vitis vinifera L. seeds extract, which is the subject of the health claim, is 
sufficiently characterised. 
• The claimed effect proposed by the applicant is “helps to decrease swollen legs”. The target 
population proposed by the applicant is healthy adults in the general population.  
• The claimed effect does not comply with the criteria laid down in Regulation (EC) 
No 1924/2006.  
Vitis vinifera L. seeds extract and “helps to decrease swollen legs” 
 
 
EFSA Journal 2012;10(12):2997               8 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Vitis vinifera L. seeds extract and “helps to decrease swollen legs” 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0343_BE). March 2012. 
Submitted by Nutrilinks Sarl. 
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